Researchers study mitochondrial function, potential new therapeutic target for Alzheimer's disease
Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment